Quick ReadPlain-language overview · read this first
Everest underwrites global reinsurance and commercial specialty insurance, selling risk protection to primary insurers and multinational corporations, and earns money from underwriting premium plus float investment income. Its moat is a combination of ratings, capital scale, and top-tier broker relationships; the A+/A+/A1 financial strength ratings of its active subsidiaries are themselves the threshold that determines who reinsurance clients choose. But earnings swing with catastrophes, social inflation, and long-tail liability reserves, with the combined ratio bouncing between 91% and 102% over three years, not the kind of good industry you can hold with your eyes closed.
The researcher's rating is Watch. The issue is not whether it's cheap, it's that certainty falls just short. Recalculated from company disclosures, the current price of about $324 corresponds to only 0.84x book value and 6.6x trailing EPS, a clear discount to Chubb and W. R. Berkley, but part of that discount is warranted: 2024 and 2025 both saw large adverse historical reserve development, concentrated in U.S. casualty long-tail liability lines, all three rating agencies have moved their outlook on the core subsidiaries to negative, and industry pricing has begun to soften again. Cheapness is only the surface; the real issue is the market discounting a lower long-term ROE.
On the positive side, management's direction is turning right: selling off the problem retail insurance business, buying adverse development protection for legacy liabilities, refocusing resources on core reinsurance and specialty lines, and buybacks that genuinely shrink the share count. Underwriting improved in Q1 2026, with annualized net ROE back to 16.8%, but it will take a few more quarters to confirm this is discipline rather than reactive firefighting. The margin of safety is not thick enough; the ideal buy range is $260-290, either wait for the price or wait for more solid evidence.
LeadA global P&C reinsurance and commercial insurance underwriting platform that earns underwriting profit plus float investment income through a moat combining ratings, capital strength, and broker relationships. The business is understandable, but earnings swing with catastrophes, long-tail reserves, and the reinsurance pricing cycle; at about $324 the stock trades at 0.84x book value and 6.6x trailing-twelve-month P/E, cheap but cheap for a reason, without a thick enough margin of safety. Research rating Watch: worth tracking, with an ideal buy range of $260-290.
Prices in the article are as of publication; see the valuation band above for the live price.
Conclusion First
Let me give the conclusion first: my current rating on Everest Group, Ltd. is "Watch." This is not because the company is bad, but because it is an insurance/reinsurance business that is understandable, but not easy; it has a moat built from scale, ratings, a relationship network, and underwriting capability, but that moat is not wide enough for you to ignore reserves, the reinsurance pricing cycle, and the impact of major catastrophe years. In 2025 the company took a number of moves that are favorable over the long run, including selling part of its commercial retail insurance renewal rights, buying adverse-development protection for North American long-tail liabilities, and repurchasing shares aggressively in 2025 and Q1 2026. But the U.S. casualty reserve problems of the past two years, the negative shift in rating outlooks, and the softening of reinsurance pricing that began in 2026 mean that the current price does not leave a very comfortable margin for error for conservative investors.
I first separate out facts, assumptions, inferences, and opinions: Facts come from the company's 2025 annual report, Q1 2026 quarterly report/results release, proxy statement, official investor relations pages, SEC disclosures, authoritative industry sources, and the latest market quotes; assumptions mainly show up in the owner earnings estimate, discount rate, long-term growth rate, and reasonable P/B range; inferences mainly show up in "the long-term ROE expectation implied by the current price" and "whether the margin of safety is adequate"; opinions are the final rating and position sizing recommendation.
Here is my preliminary judgment in the summary format you requested:
Investment rating: Watch.
Core judgment: Everest is a global P&C reinsurance/insurance underwriting platform. The business model is understandable, but earnings are highly dependent on underwriting discipline, reserve accuracy, and the industry cycle. Its current valuation is not expensive: on my own recalculation based on company disclosures, the current share price corresponds to about 0.84x book value at the end of Q1 2026 and about 6.6x trailing-twelve-month EPS, which suggests the market has already priced in a fair amount of concern. The issue is that these concerns are not unfounded — both 2024 and 2025 saw significant prior-year reserve development, and all three major rating agencies have moved their outlook on the core operating subsidiaries to negative. If you are a balanced, conservative long-term investor, I would rather act at a lower price, or after another two to three quarters confirm that "reserve repair is complete."
Does the current price offer a margin of safety: Not obviously.
Suitable investor type: Long-term value investors who can read insurance liabilities, reserves, catastrophe exposure, and the reinsurance cycle; not well suited for ordinary investors who want a "buy it and forget it" core holding.
Biggest uncertainties: Whether U.S. casualty and legacy reserves have truly been "cleaned out"; whether reinsurance pricing softening starting in 2026 will compress mid-term ROE; and whether the negative rating outlook turns into an actual downgrade, affecting business flow and cost of capital.
Business Understanding and Industry Landscape
Everest's core business is underwriting reinsurance and commercial insurance risk. As of the end of 2025, the company operated under two reporting segments: Reinsurance and Insurance; by Q1 2026, after selling part of its commercial retail insurance renewal rights, the structure changed to three reporting segments — Reinsurance Treaty, Global Wholesale & Specialty, and Legacy — of which only the first two are genuinely ongoing, externally sold product lines. In 2025 reinsurance accounted for about 72.4% of the company's gross written premium and insurance accounted for about 27.1%; the company's business network covers more than 100 countries across six continents.
Who are the customers? Reinsurance customers are mainly cedents, i.e., primary insurers; insurance customers are multinational corporations and mid-size commercial clients, distributed mainly through wholesale brokers, retail brokers, surplus lines brokers, and program administrators. How does the company get paid? Essentially it earns money through underwriting premium income plus float investment income: it collects premiums up front and pays claims later under policies and reinsurance contracts; if the underwriting side sustains a combined ratio below 100% over the long run, and the investment side steadily earns interest, alternative investment income, and other investment income, the company can convert float into shareholder returns. In 2025 the company's net premiums earned were $15.560 billion, and net investment income was $2.124 billion; in Q1 2026 net investment income further reached $567 million.
Is revenue repeatable, stable, and predictable? The answer is: it is repeatable, but only moderately stable, and less predictable than a typical consumer or software business. Renewals and long-term customer relationships genuinely exist, and the company also emphasizes that its long-standing client and broker relationships are a competitive foundation; but reinsurance and commercial insurance pricing is highly dependent on industry supply-demand dynamics and accident-year outcomes, so it should not be treated as highly predictable "subscription-like cash flow." This is clear from the combined ratios of 90.9%, 102.3%, and 98.6% in 2023, 2024, and 2025 respectively: the underlying business is fine, but extreme weather, social inflation, and legacy reserves are all capable of causing profit to swing wildly.
On the cost side, the core costs are not raw materials as in traditional manufacturing, but rather claims costs, reinsurance costs, commissions/brokerage fees, operating expenses, and interest costs. In 2025, incurred losses and LAE were $10.859 billion, commission, brokerage, taxes and fees were $3.461 billion, other underwriting expenses were $1.029 billion, and interest, expenses and amortization of debt issuance costs were $151 million. This cost structure shows that Everest's economic essence is not "producing off low-cost fixed assets," but rather earning money "through pricing power, underwriting discipline, risk selection, and asset-liability matching."
Does the company depend on a small number of customers, suppliers, channels, policies, or key individuals? From a customer standpoint, dependence is low: in 2025 no single customer contributed more than 3.6% of gross premiums, and in the Insurance segment no single program administrator exceeded 4.3%. But from a channel standpoint, brokers matter a great deal: the company's top ten brokers together contributed about 60.9% of gross premiums, with Marsh McLennan at about 22.4% and Aon at about 18.7%. In other words, it is not a company overly concentrated in customers, but it is definitely a company dependent on the broker ecosystem, ratings, and reputation.
If the stock market closed for five years, would I want to hold this business? Yes, but it would not be easy. I would be willing to hold it because its balance sheet is generally strong, its global footprint is broad, its business relationships run deep, its long-term float has real value, and management has already begun to pull back from the historically more problematic commercial retail insurance and North American casualty exposures. I would not find it easy, because this remains a business heavily affected by catastrophes, social inflation, long-tail reserves, and the industry pricing cycle. For a long-term owner, it is more of a "business you can own, but must watch closely" than one you can "hold with your eyes closed."
Business understandability score: 3/5. Insurance itself is not hard to understand, but once you layer reinsurance on top of long-tail liability reserves, ADCs, and legacy run-off, the complexity rises noticeably.
From an industry standpoint, P&C reinsurance and specialty commercial insurance is a business with durable long-term demand but a strong cycle. Demand on the ground is not going away: natural catastrophes, corporate liability, professional liability, specialty and niche risk, and reinsurance capital needs are all real. But the January 2026 renewal season already showed the industry moving into a more buyer-friendly phase — Gallagher Re explicitly stated that the headline of the January 2026 renewal was ample capacity and significant price declines, with property lines seeing double-digit risk-adjusted rate decreases. AM Best similarly noted that January 2026 property reinsurance rates generally fell 10%-20%. At the same time, Swiss Re data shows global insured nat-cat losses in 2025 still totaled a hefty $107 billion, with the Los Angeles wildfires alone accounting for about $40 billion, and severe convective storms exceeding $50 billion in insured losses for a third consecutive year — meaning "underlying risk has not gotten lighter, there is just more capital chasing it."
Major competitors include Arch Capital, RenaissanceRe, Chubb, and W. R. Berkley, among others; on AM Best's global reinsurer ranking, Everest has already entered the top tier — in the 2025 edition of "largest reinsurers" data, its ranking rose from the prior year, with AM Best's public summary even noting that Everest has moved up to a leading position among non-IFRS 17 players. This shows it is not a marginal player, but a major participant in the global reinsurance capital pool.
Industry attractiveness score: 3/5. Demand is real and long-term, but price volatility, changes in capital supply, regulation, and climate events make it hard to call this a "capital-light, high-stickiness, great industry." More precisely, Everest today is more of a "strong company in a middling industry" than a "great company in a great industry."
Moat and Management
If you break down the moat using a "Buffett-style" framework, Everest's moat exists, but is not wide, and is more of a composite moat.
Let's look at the components of the moat first. Brand advantage: in reinsurance, brand is not a mass-consumer brand but rather the ability to pay claims, underwriting credibility, and long-term relationships. Everest's active subsidiaries carry financial strength ratings of A.M. Best A+, S&P A+, and Moody's A1, and the company explicitly states that these ratings are an important basis for client selection; in reinsurance contracts, if the rating falls below A-, some cedents can terminate the contract or require collateral. For a reinsurer, this is a real entry barrier.
Scale advantage: as of the end of 2025, total investments plus cash were $45.429 billion, total assets were $62.514 billion, and shareholders' equity was $15.461 billion; in Q1 2026, management still described itself as a global underwriting leader with a 50-year history. This scale brings underwriting capacity, global diversification, entry thresholds for winning business, and the ability to participate in large risks.
Channel advantage: the top ten brokers account for 60.9% of gross premiums, with Marsh and Aon holding a very high share; this is both a dependency and part of the moat. Without ratings, capital, and an underwriting team, top brokers will not consistently bring you large accounts and key placements.
Switching costs: they exist, but are not extreme. Insurance and reinsurance contracts can in theory be signed year to year and are price-sensitive; but on complex risks, catastrophe exposure, and long-term claims service, clients do have a preference for a stable underwriter and claims handler, so real-world switching costs are higher than you might expect, but lower than in software.
Regulatory/license barriers: this is real. Everest operates under licenses in Bermuda, the United States, Ireland, Lloyd's, Canada, Australia, Singapore, and other jurisdictions; these local licenses, capital requirements, examinations, and cross-border structures are themselves an entry barrier.
Data advantage, network effects, patent advantage: data and modeling capability have value, but are not sufficient on their own to create an uncopyable advantage; network effects and patent barriers are largely not core factors. Reinsurance relies more on a combination of people, process, data, ratings, capital, and discipline.
So my judgment is: Everest's moat is more of a combination of "ratings + capital + a global relationship network + underwriting/claims capability", rather than a single monopolistic moat. It does have some pricing power, but that pricing power depends on the cycle: it was stronger during the 2023-2025 hardening phase, and has already started coming under pressure as industry capacity returns in 2026. Can the company raise prices amid inflation? In short-tail property and specialty lines, usually yes, and more quickly; in long-tail casualty lines, social inflation and extending claims tails can create the risk of "raising prices on paper while real profit doesn't rise, or even falls."
Can the company stay profitable in an economic downturn? Possibly, but it's not guaranteed. The full-year 2025 combined ratio was still below 100% at 98.6%, and Q1 2026 came in at 91.2%, showing that the underlying underwriting capability is still there; but 2024 reached 102.3%, showing that once a major catastrophe or reserve deterioration hits, profit can be swallowed up quickly. The high margins of the past reflect both structural advantages and the cyclical tailwind of the hard market since 2023.
Moat strength score: 3/5. I see competitive strength that can be sustained, but not the kind of "super moat" that competitors couldn't dent in ten years.
On management, my assessment is: the direction is turning right, but trust has not yet returned to "unconditional credit." In January 2025, former CEO Juan Andrade departed; Jim Williamson first served as interim CEO and was later formally appointed permanent CEO. The chairmanship also changed hands the same year. This kind of senior turnover itself means management and culture need to rebuild stable expectations.
On the positive side, the moves Williamson has made since taking over have generally pointed toward long-term value rather than short-term scale: selling part of the commercial retail insurance renewal rights to AIG, refocusing on core global reinsurance and wholesale/specialty; buying adverse development protection for historical long-tail liabilities in North American Insurance and Legacy; repurchasing $797 million of stock and paying $335 million in dividends in 2025, returning about $1.132 billion to shareholders in total; and repurchasing another $331 million and paying $80 million in dividends in Q1 2026. These moves show management is not simply chasing "bigger premium volume," but is restructuring the portfolio and recycling capital.
But the negative side cannot be ignored either. First, insider ownership among directors and executives is not high: the proxy statement shows all directors, director nominees, and executive officers together own about 297,000 shares, only about 0.7% of shares outstanding; the CEO's own holdings are far from "owner-operator" territory. Second, while the company does have ownership guidelines — at least 6x salary for the CEO and 3x salary for other executives — this only shows the governance framework is reasonable, and cannot automatically make up for insufficient real ownership. Third, the 2026 proxy materials also disclose new equity incentive capacity, with total potential dilution of about 4.3%, which is not out of control but should not be overlooked either.
My final assessment of capital allocation is: noticeably more rational than a year ago, but it still needs time to prove this is not "reactive repair after a problem" but rather repeatable, long-term discipline. The core financial metric for management bonuses is Adjusted Net Operating Income ROE; the CEO's 2025 financial target ROE was 15%, while actual ROE came in at 12.4%, and the committee accordingly paid out only a below-target portion of the financial bonus. This shows the board is not being entirely lenient on incentives, and its methodology is reasonably sound.
Management and capital allocation score: 3/5. Direction earns points, historical baggage costs points, and ownership alignment is middling.
Financial Quality and Owner Earnings
The table below is based mainly on the five-year financial summary in the company's 2025 annual report, along with the detailed 2025/2024/2023 financial summaries; this table is best for viewing "the trend over the back half of a complete cycle."
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Gross written premium (GWP, $bn) | 13.050 | 13.952 | 16.637 | 18.232 | 17.706 |
| Net investment income ($bn) | 1.165 | 0.830 | 1.434 | 1.954 | 2.124 |
| After-tax operating income ($bn) | 1.153 | 1.065 | 2.776 | 1.289 | 1.875 |
| Net income ($bn) | 1.379 | 0.597 | 2.517 | 1.373 | 1.591 |
| Combined ratio | 97.8% | 96.0% | 90.9% | 102.3% | 98.6% |
| Attritional combined ratio | 87.6% | 87.4% | 86.9% | 87.6% | 89.4% |
| Operating ROE | 12.2% | 10.6% | 23.1% | 9.0% | 12.4% |
| Net ROE | 14.6% | 6.0% | 20.9% | 9.6% | 10.5% |
| Book value per share, BVPS ($) | 258.21 | 215.54 | 304.29 | 322.97 | 379.83 |
| Dividend per share ($) | 6.20 | 6.50 | 6.80 | 7.75 | 8.00 |
| Operating cash flow ($bn) | not centrally disclosed | not centrally disclosed | 4.553 | 4.957 | 3.068 |
A current snapshot: in Q1 2026, the company reported net income of $653 million, net operating income of $648 million, annualized net ROE of 16.8%, and a combined ratio of 91.2%; ending shareholders' equity was $15.291 billion, book value per share was $383.75, and shares outstanding at period end were about 39.8 million.
Looking at the long-term trend, there are three encouraging points. First, premium and book value are growing: on a rough 2021-2025 five-year summary basis, GWP CAGR was about 7.9% and BVPS CAGR was about 10.1%; net investment income CAGR was about 16.2%, showing that the high-rate environment and asset growth have clearly helped earnings. Second, shareholder returns are not entirely dependent on accounting illusions: book value and BVPS continued to grow in 2025 even after dividends and buybacks; BVPS also kept rising in Q1 2026 alongside continued dividends and buybacks. Third, interest coverage is not bad: using pre-tax income plus interest as a rough EBIT/interest calculation, the ratio was roughly 17x, 11x, and 13.5x in 2023, 2024, and 2025 respectively.
The problems are equally clear. First, profit smoothness is poor. The 2024 combined ratio exceeded 100%, and while it came back down to 98.6% in 2025, net income still included $657 million of adverse prior-year loss reserve development; that figure was even higher in 2024, at $1.5 billion. Second, reserve quality is the core issue. The company itself acknowledges that 2025 reserve strengthening mainly came from excess casualty and U.S. liability, concentrated in accident years 2022-2024; this is not "pure natural-catastrophe noise," but the more troublesome long-tail liability problem. Third, accounting profit and operating cash flow cannot simply be matched one-to-one, because an insurer's operating cash flow is significantly distorted by float growth. 2025 operating cash flow was $3.068 billion, far above net income of $1.591 billion, but a large part of that came from changes in insurance liabilities such as loss reserves and unearned premium reserves, and should not be mechanically treated as free cash flow.
Now the balance sheet. At the end of 2025, total assets were $62.514 billion and total liabilities were $47.054 billion, of which reserve for losses and LAE was $34.312 billion; total debt was $3.589 billion, for a debt/equity ratio of about 0.23x. This shows that Everest's off-balance-sheet risk lies in insurance liability quality, not in leverage in the ordinary industrial-company sense. In 2025, premiums receivable rose from $5.378 billion to $5.727 billion; amounts due to reinsurers fell from $701 million to $642 million. Inventory is not applicable to an insurer; metrics like net debt/EBITDA and EV/EBITDA also have limited relevance for insurers, because buying and selling investment securities, insurance liabilities, and debt capital all play the role of "raw materials/production tools" in operations, and cannot be understood linearly the way manufacturing can.
On share count, the company is genuinely buying back stock, not just talking about it. Full-year 2025 buybacks were $797 million, with another $331 million in Q1 2026; the weighted diluted share count in the 2025 five-year summary was about 40.7 million, down from 43.0 million in 2024, and the basic weighted share count fell further to about 39.8 million in Q1 2026. So, at least for now, buybacks are not there to mask equity-incentive dilution, but genuinely reducing the denominator.
On whether "profit is real cash profit," my conclusion is: it's real, but needs an insurance-specific adjustment. If you only look at net income, you risk under- or over-estimating; if you only look at operating cash flow, you will almost certainly overestimate. A more reasonable view is that Everest's real earnings power is close to its after-tax operating income, discounted for the retention needed to maintain long-term capital and ratings. In 2025 the company returned about $1.132 billion to shareholders in total, and about $411 million in Q1 2026, while BVPS kept rising; this shows it genuinely has distributable cash flow capacity, but "distributable" does not mean "distribute all of operating cash flow."
Using an "owner earnings" approach, here is a conservative estimate:
Starting point: 2025 after-tax operating income of $1.875 billion.
Not adding back stock-based compensation, because it is a real economic cost, not a free lunch; 2025 non-cash equity compensation was about $61 million, which should be treated as a deduction to owner earnings, not an add-back.
Maintenance capital spending: the company does not separately disclose traditional capex the way an industrial firm would; an insurer's day-to-day "growth investment" shows up more as maintaining regulatory capital, rating capital, and systems/underwriting platform investment; so I do not treat purchases of investment securities as capex, nor treat float growth as fully free cash.
Working capital/float adjustment: I do not count all of the 2025 operating cash flow of $3.068 billion as owner earnings, because it includes about $3.602 billion of reserve growth and other float-related changes; for an insurer, this cash has usage value, but is not all freely distributable.
Based on this approach, I estimate Everest's conservative owner earnings at roughly $1 billion, with a reasonable range of about $0.9 billion-$1.2 billion. This is certainly more conservative than "operating cash flow minus traditional capex," but I believe it is closer to the cash that long-term shareholders can actually take out without damaging ratings or capital adequacy. At the current share price of $324.23 and about 39.8 million shares, equity market cap is about $12.9 billion; against my owner earnings estimate, that is roughly 10.8x-14.3x owner earnings, with a midpoint of about 12.9x, or an owner earnings yield of about 7%-9%. This valuation is not expensive, but it's not "extremely cheap" either.
Valuation and Margin of Safety
Let's start with the most direct current market pricing. The current share price is about $324.23. I do not directly use the P/E figure shown by market data feeds, because it does not match the EPS basis the company discloses; all valuation multiples below are recalculated from company-disclosed data. Using full-year 2025 diluted EPS of $37.80, plus Q1 2026 diluted EPS of $16.21, minus Q1 2025 diluted EPS of $4.90, gives trailing-twelve-month EPS of about $49.11; on that basis the current P/E is about 6.6x. Using Q1 2026-end BVPS of $383.75, the current P/B is about 0.84x; on an annualized dividend of $8, the rough dividend yield is about 2.5%.
This pricing carries an important implication: the market is not pricing Everest as a high-quality insurance stock. For comparison, on the latest prices and each company's most recently published book value/net worth basis, Arch Capital trades at roughly 1.35x P/B, RenaissanceRe at about 1.12x P/B, Chubb at about 1.64x P/B, and W. R. Berkley as high as about 2.43x P/B. Everest's discount is very pronounced — this could be either an opportunity or a case of "cheap for a reason."
As you requested, I will value the company using three methods, but first want to stress: for a reinsurer, methods based on book value and sustainable ROE are generally more explanatory than EV/EBITDA, because an insurer's investment assets, reserves, and debt are all part of its operating system, and a traditional corporate valuation framework cannot simply be transplanted.
Method one: discounted owner earnings. This is the hardest and most sensitive method, because the definition of owner earnings itself depends on "how much capital needs to be retained to be safe." I use three sets of assumptions — conservative, neutral, and optimistic:
Conservative case: owner earnings starting at $850 million, growing 1% over the next 10 years, discount rate 11%, terminal growth 1%;
Neutral case: owner earnings starting at $1 billion, growing 3% over the next 10 years, discount rate 10%, terminal growth 2%;
Optimistic case: owner earnings starting at $1.2 billion, growing 4% over the next 10 years, discount rate 9%, terminal growth 2.5%.
Under this set of parameters, I get roughly the following per-share values:
Conservative: about $216/share;
Neutral: about $344/share;
Optimistic: about $532/share.
This spread is enormous, which itself shows this company should not be judged on a DCF alone. What the DCF tells me is not "a precise value," but this: if you believe Everest's true distributable earnings have already stabilized above $1 billion and reserves will not keep swinging, the current price is not high; if you believe its owner earnings will keep being eroded by more legacy problems and capital needs, the current price may not be cheap either. The most fragile assumption in this method is not the growth rate, but "how much of the profit is truly distributable."
Method two: relative valuation. I weight three metrics most heavily: P/B, P/E, and ROE.
Everest: about 0.84x P/B, about 6.6x TTM P/E, 2025 net ROE 10.5%, Q1 2026 annualized net ROE 16.8%.
Arch Capital: about 1.35x P/B, Q1 2026 annualized net ROE 17.8%.
RenaissanceRe: about 1.12x P/B, Q1 2026 annualized net ROE 10.5%, but operating ROE 21.8%.
Chubb: about 1.64x P/B, Q1 2026 annualized ROE 12.6%, core operating ROE 14.0%.
W. R. Berkley: about 2.43x P/B, Q1 2026 annualized ROE 21.2%.
The relative-valuation conclusion is not complicated: Everest is cheap, but its quality and certainty are also weaker than Chubb / WRB, and at least part of its discount is warranted. If you view Everest as a company that has "completed reserve repair, with sustainable net ROE of 10%-12%," then a valuation of 0.9x-1.05x book value is reasonable, corresponding to roughly $345-$403/share; if you view it as a company that "still needs a longer repair period, with sustainable net ROE of only 8%-10%," then 0.75x-0.9x book value is more appropriate, corresponding to roughly $288-$345/share.
Method three: asset or liquidation value. For a reinsurer, this method matters a great deal. Everest's book value per share at the end of Q1 2026 was $383.75, and book value per share excluding fixed-income AOCI swings was $393.02. The good news is that the company's investment portfolio is largely carried at fair value or near-fair value to begin with, so book value does not distort the asset side the way it can for an industrial company. The bad news is that reserves on the liability side are not "as certain as cash," especially for casualty and legacy lines. Given the company already has ADC protection but historical reserve development remains non-trivial, I think 0.8x-1.0x adjusted book value is a reasonable conservative-to-neutral range for the asset method, corresponding to roughly $314-$393/share. If reserves prove stable over the next 2-3 quarters and the negative outlook is removed, a range of 1.05x-1.1x would not be unreasonable either.
Combining all three methods, here is my final value range:
Conservative intrinsic value range: $280-320/share. This corresponds to a scenario where "historical issues have not fully cleared, and sustainable ROE is close to 8%-9%."
Reasonable intrinsic value range: $330-390/share. This corresponds to a scenario where "reserve repair is essentially complete, and sustainable ROE is 10%-12%."
Optimistic intrinsic value range: $400-470/share. This corresponds to a scenario where "management's restructuring succeeds, capital allocation stays effective, and the market is willing to re-rate the stock above 1x book value."
At the current price of $324.23:
Relative to the conservative range, it is no longer particularly cheap, sitting near the upper end;
Relative to the reasonable range, it trades at roughly a 2%-18% discount;
Relative to the optimistic range, the discount is larger, but that upside requires more evidence to materialize.
So my conclusion on margin of safety is: there is some, but not enough. For a balanced, conservative investor, I typically want a single reinsurance stock to already sit comfortably below "conservative value," or at least trade at a 20%-25% discount to the "reasonable value midpoint." By that standard, Everest is not yet at a price where I'd want to act decisively.
My suggested price bands are as follows:
Ideal buy price range: $260-290/share. This leaves a thicker cushion for reserve error, industry rate declines, and catastrophe volatility.
Acceptable holding price range: $290-380/share. If you already hold it, this range is more about "continuing to watch operating execution" than "rushing to sell."
Clearly overvalued price range: $430/share and above. If it trades here without a structural improvement in ROE, I would consider the risk/reward to be turning unfavorable.
Comparing it with other opportunities, my conclusion is:
Against the strongest peers, Everest is cheaper, but its business quality and predictability are for now weaker than Chubb and W. R. Berkley; if you only want one low-maintenance P&C insurance stock, I would prioritize quality over Everest's discount.
Against the S&P 500, Everest's upside comes mainly from "discount recovery + buybacks + book value growth," while SPY's advantage is diversification and not having to bet on a reserve/catastrophe/rating story; I do not currently think Everest is clearly superior to buying SPY for most investors.
Against the risk-free rate/high-grade bonds, the latest 10-year U.S. Treasury yield is about 4.45%, and AAA-rated USD credit bonds yield about 4.99% effective. Everest's neutral-case implied annualized return is roughly 8%-11% — there is a risk premium, but not an especially generous one; given its tail risk, this premium is not enough for me to disregard margin-of-safety requirements.
If I could only hold 5 positions: at the current price, I would not put it in the top five. If it fell to $260-290, or if a few more quarters confirmed that reserve repair is real, I would reconsider.
Risks, Checklist, and Final Verdict
Here are the most important risks, prioritized by "permanent capital loss":
Reserve risk: both 2024 and 2025 saw significant prior-year reserve development, concentrated particularly in U.S. casualty, excess casualty, liability lines, and some Russia/Ukraine-related aviation losses; if this kind of risk keeps spilling over, it will directly damage book value and ratings.
Industry cycle risk: the January 2026 renewal already confirmed declining property reinsurance rates and ample market capacity; if pricing keeps softening in coming quarters without a matching improvement in loss trends, ROE will be squeezed from both directions.
Rating risk: A.M. Best, S&P, and Moody's have all moved their outlook on core operating subsidiaries to negative; ratings are critical to reinsurance business flow, contract terms, and access to capital markets.
Catastrophe and climate risk: Swiss Re data shows global insured nat-cat losses in 2025 were still as high as $107 billion, with secondary perils increasingly dominating losses. Reinsurers can price this risk, but cannot eliminate tail events.
Social inflation and litigation environment risk: the company itself repeatedly cites social inflation as a key variable in reserve and claims uncertainty, which is especially dangerous for long-tail liability lines.
Management and transition execution risk: both the CEO and chairman changed in 2025; the portfolio-restructuring direction is correct, but the execution track record is still short.
Valuation trap risk: it is cheap now, and that may not be a market mistake, but the market pre-discounting "a lower long-term ROE." If sustainable ROE of 10%-12% ultimately does not materialize, 0.84x book value is not necessarily low.
The strongest bear case is not hard to write: Everest is not a high-quality insurance stock that the market has mindlessly mispriced, but a reinsurer that is repairing historical mistakes, whose business quality still needs to prove itself, and whose industry is only just beginning to soften again. Cheapness is only the surface; the real question is: if casualty reserves are not yet clean, if the ADC is not enough to cover subsequent development, and if industry price declines outpace the company's portfolio optimization, then today's apparent 0.84x book value may in the future correspond to a lower real book value and a lower reasonable valuation multiple.
What facts would overturn this investment judgment? For me, they include at least the following:
Another large long-tail reserve strengthening, showing that the 2025 repair was never really complete;
Rating outlooks moving from negative to an actual downgrade;
Buybacks staying aggressive while capital adequacy and underwriting discipline deteriorate, showing capital allocation has degenerated into "propping up EPS";
In a relatively normal catastrophe year, the company's adjusted operating ROE remains persistently below 10%;
The pace of risk run-off in Legacy and North American casualty running clearly slower than management currently describes.
Here is the conclusion in the checklist format you requested:
| Check item | Verdict |
|---|---|
| Can I understand this business | Pass |
| Does it have durable long-term demand | Pass |
| Does it have a durable moat | Uncertain |
| Does it have pricing power | Uncertain |
| Can it generate stable free cash flow | Uncertain |
| Is its return on capital excellent | Uncertain |
| Is management trustworthy | Uncertain |
| Is capital allocation rational | Pass |
| Is the balance sheet sound | Pass |
| Is valuation below intrinsic value | Uncertain |
| Is the margin of safety sufficient | Fail |
| Would long-term holding let me sleep easy | Fail |
| Which key facts would make me sell | Renewed reserve deterioration, a rating downgrade, ROE persistently below 10% |
| Am I buying only because the price is rising or out of market sentiment | Fails this motive test |
A few limitations/open questions need to be stated honestly. First, an insurer's traditional FCF and EV/EBITDA metrics are inherently distorted, and I did not mechanically use these multiples in this report. Second, more granular breakdowns of receivables, payables, and cash flow for 2021-2022 are not centrally presented in the latest annual report summary, so this report relies mainly on the detailed 2023-2025 period and the 2021-2025 summary period for those items. Third, the most sensitive point in the valuation is not the growth rate, but "exactly how much profit is truly owner earnings that requires no further capital retention." None of this changes the main conclusion of this report, but it does affect the precision of the valuation range.
【Final Rating】 Watch
【One-Sentence Thesis】 Everest today looks like a global reinsurer that is "cheap on the books, improving in governance, but has not yet fully digested its historical reserves and industry inflection point." Whether it is worth buying more depends largely on your confidence in its reserve repair and sustainable ROE.
【Core Bull Case】
Current valuation is not high — on my recalculation of company disclosures, about 0.84x P/B, 6.6x TTM P/E.
The global platform, A+/A+/A1 ratings, broker relationships, and capital strength still constitute real competitive advantages.
Management is doing the right things: selling problem businesses, buying ADC protection, and concentrating resources in core reinsurance and wholesale/specialty.
The buyback is a real buyback — the denominator is shrinking, with sizable shareholder returns in both 2025 and Q1 2026.
Q1 2026 underwriting and earnings performance improved markedly, with annualized net ROE back to 16.8% and combined ratio down to 91.2%.
【Core Bear Case】
2024 and 2025 both saw large, adverse historical reserve development; the issue has not yet been fully proven resolved by the passage of time.
All three rating agencies have moved their outlook to negative, and the reinsurance business is extremely rating-sensitive.
Industry reinsurance pricing has already begun to soften in 2026, so future earnings leverage may not match the past two years.
Reinsurance is inherently a high-volatility industry — catastrophes and social inflation can swing profits sharply.
Overall insider ownership among management and executives is not high; this is not a typical owner-operator setup.
【Key Assumptions】
The 2025 reserve strengthening is near its end, not the midpoint.
The ADC and business exits are enough to meaningfully reduce legacy/North America casualty tail risk.
Sustainable net ROE can hold in the 10%-12% range.
The rating outlook does not move further from negative to an actual downgrade.
Buybacks will continue to be grounded in a discount to book value and capital adequacy, rather than purely dressing up EPS.
【Reasonable Buy Price】 $260-290/share. The basis: this range provides a more decent cushion against my conservative/reasonable value ranges, and is better suited to a balanced, conservative investor.
【Target Holding Period】 At least 5-10 years, but only if you are willing to keep tracking reserves, ratings, and the pricing cycle throughout, rather than "buy and forget."
【Expected Annualized Return】
Conservative case: 4%-6%.
Neutral case: 8%-11%.
Optimistic case: 12%-15%. This is derived from book value growth, shareholder returns, and some degree of valuation recovery — it is not a short-term price prediction.
【Maximum Loss Risk】 If reserves deteriorate again, book value shrinks, and ratings are damaged, and the market applies an even lower P/B, a 35%-45% permanent capital loss is not unimaginable; under an extreme multi-front hit, the loss could be larger still. The reason would not be a debt blowup, but rather simultaneous deterioration in liability-side quality and valuation multiple.
【Tracking Metrics】
Prior-year reserve development, especially in U.S. casualty/legacy.
Adjusted operating ROE.
Combined ratio and attritional combined ratio.
Ratings and rating outlooks.
Pricing, structure, and premium mix in the Reinsurance Treaty segment.
Underwriting profitability at Global Wholesale & Specialty.
Whether share buybacks continue to occur at a discount to book value.
Book value per share and BVPS excluding AOCI.
Net investment income and investment portfolio duration/credit quality.
The actual protective effect of the ADC and the pace of legacy risk run-off.
【Signals That Would Trigger Reassessment】
Consecutive quarters of new, large casualty reserve strengthening.
The rating outlook deteriorating into an actual downgrade.
Industry pricing continuing to weaken sharply while the company still pursues scale growth.
Buybacks remaining large while BVPS and capital adequacy deteriorate.
Management's messaging repeatedly diverging from actual underwriting results.
【Final Recommendation】 Put plainly, Everest is worth tracking, but right now is better suited to "watching and waiting" than to rushing into a large position. It is not a bad business, nor is it a significantly bubbly stock; the issue is that it falls a bit short of "high certainty" and a bit short of "cheap enough." For capital like yours — 10-plus year horizon, balanced and conservative — I would put it on a watch list: either wait for a better price, or wait for more solid operating evidence. If I had to choose one, I would rather wait for the evidence first, and pay the price second.
Full report
Sign in to read the full report
Sign up free to unlock the full text, the Baillie growth scorecard, and full-text search.
Log in / Sign up free